|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2022-04-28 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2014-07-04 |
A Phase 1, Partially Blinded, Placebo-Controlled, study of Intravenously Administered BMS-943539 to assess the pharmacokinetics and in particular the mean T-HALF of BMS-943539 across all doses in healthy male subjects.
Protocol IM101042: A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept vs. Placebo on a Background of Oral Glucocorticosteroids in the Treatment of Subjects with Systemic Lupus Erythematosus and the Prevention of Subsequent Lupus Flares.
A Phase 3, Active (Warfarin) Controlled, Randomized,Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban inPreventing Stroke and Systemic Embolism in Subjects with Nonvalvular AtrialFibrillation
100 项与 Bristol-Myers Squibb Australia Pty Ltd. 相关的临床结果
0 项与 Bristol-Myers Squibb Australia Pty Ltd. 相关的专利(医药)
100 项与 Bristol-Myers Squibb Australia Pty Ltd. 相关的药物交易
100 项与 Bristol-Myers Squibb Australia Pty Ltd. 相关的转化医学